

22nd February 2006



Company Details

Name: Genophrenix
Year founded: 2006
Category: Medicine
University partner: Sheffield
Biofusion shareholding: 60%

Company Background

Genophrenix has identified several proteins and their genes, which interact with a key component that is implicated in schizophrenia. By understanding which genes are involved in the disease and targeting these rather than attempting to treat the symptoms, Genophrenix believes that more specific and efficacious drugs can be developed with reduced side effects. Genophrenix will initially focus on developing targets and compounds to treat schizophrenia and aims to provide commercially viable licensing opportunities that will be attractive to the global pharmaceutical industry.

Genophrenix has identified an area of the brain that may be common amongst all schizophrenia sufferers and is developing a way of targeting this specific area so that we have a better performing drug with fewer side effects.